Interpretation of Hepatitis B Panel Results

Understanding the Serologic Pattern

The Centers for Disease Control and Prevention recommends that a HBsAg negative, anti-HBc negative, anti-HBs positive pattern indicates immunity acquired through vaccination rather than natural infection 1, 2, 3
The presence of anti-HBs (≥10 mIU/mL) alone generally indicates protective immunity against HBV infection, as stated by the American Association for the Study of Liver Diseases 4, 5
When both anti-HBs and anti-HBc are positive, this would indicate immunity from past natural infection, which is not the case here, according to the Infectious Diseases Society of America 4, 1

The patient is protected against HBV infection and does not require vaccination, as recommended by the Centers for Disease Control and Prevention 6, 1
The patient is not infectious and cannot transmit HBV to others, as stated by the American College of Physicians 4, 2
This pattern confirms successful response to previous HBV vaccination, according to the Centers for Disease Control and Prevention 1, 2

Anti-HBs levels may wane over time, but immunocompetent individuals typically maintain protection even with declining antibody levels, as reported by the American Association for the Study of Liver Diseases 1, 5
If the patient requires immunosuppressive therapy in the future, they remain protected against HBV reactivation due to the absence of anti-HBc, as stated by the National Comprehensive Cancer Network 7, 8

If the patient were to develop conditions requiring significant immunosuppression, monitoring anti-HBs levels might be warranted, as recommended by the American Society of Clinical Oncology 9, 10
In transplant recipients, anti-HBs titers should be checked periodically as they may decline more rapidly, according to the American Society of Transplantation 10

Routine booster doses are not recommended for immunocompetent individuals with documented seroconversion after vaccination, as stated by the Centers for Disease Control and Prevention 6, 1
Booster doses should be considered in specific high-risk scenarios, such as prior to starting immunosuppressive therapy if anti-HBs levels are low, as recommended by the National Comprehensive Cancer Network 7, 8

The American Journal of Kidney Diseases recommends that dialysis patients with vaccine-derived immunity require annual screening with anti-HBs to monitor for potential loss of immunity 11

The American Journal of Kidney Diseases suggests that for immunocompromised patients, such as those on hemodialysis, annual anti-HBs testing with booster doses when levels fall <10 mIU/mL is recommended, highlighting the importance of monitoring in these populations 11